Associations of fibrinogen, FII, FV, FVIII, FX, protein S, antithrombin (AT) and D-dimers with spirometric stages, GOLD ABCD groups, CAT score and number of exacerbations in patients with stable COPD
| n (%) | I | II | V | VIII | X | Protein S | AT | D-dimers | |
| FEV1 % predicted | |||||||||
| ≥50% | 62 (60.2) | 403±82 | 117±17 | 127±24 | 144 (110–156) | 102 (86–118) | 95 (83–107) | 94±11.7 | 375 (230–560) |
| <50% | 41 (39.2) | 391±81 | 130±27 | 138±24 | 154 (126–182) | 124 (110–143) | 95 (85–105) | 95±11.3 | 350 (200–630) |
| p-value# | 0.574 | 0.003 | 0.018 | 0.729 | 0.001 | 0.656 | 0.813 | 0.696 | |
| GOLD groups | |||||||||
| A | 28 (27.2) | 407±84 | 114±17 | 123±22 | 135±29 | 94 (88–113) | 95 (88–112) | 94 (89–100) | 340 (252–470) |
| B | 27 (26.2) | 397±82 | 116±16 | 133±27 | 140±33 | 122 (95–137) | 91 (76–104) | 94 (89–97) | 450 (240–750) |
| C | 15 (14.6) | 420±75 | 129±22 | 133±22 | 145±28 | 128 (108–140) | 98 (95–109) | 96 (94–101) | 330 (220–780) |
| D | 33 (32) | 383±83 | 130±27 | 135±26 | 150±33 | 114 (102–139) | 95 (80–105) | 94 (85–103) | 360 (225–630) |
| p-value¶ | 0.482 | 0.017 | 0.147 | 0.180 | 0.002 | 0.177 | 0.770 | 0.529 | |
| CAT score | |||||||||
| <10 | 43 (41.7) | 389±82 | 120±20 | 127±22 | 140(117–159) | 101 (90–128) | 96 (92–109) | 94 (89–101) | 330 (250–530) |
| ≥10 | 60 (58.3) | 411±80 | 124±24 | 134±26 | 153(117–170) | 118 (100–138) | 94.5 (77–104) | 94 (87–100) | 420 (230–655) |
| p-value# | 0.199 | 0.418 | 0.066 | 0.167 | 0.034 | 0.033 | 0.608 | 0.304 | |
| Exacerbations | |||||||||
| <2 | 78 (75.7) | 399±81 | 114±16 | 124±23 | 144 (117–167) | 99 (89–123) | 95±19 | 94±12 | 380 (248–618) |
| ≥2 | 25 (24.3) | 397±85 | 127±24 | 136±25 | 158 (120–170) | 121 (101–139) | 94±17 | 96±11 | 340 (225–535) |
| p-value# | 0.866 | 0.005 | 0.018 | 0.368 | 0.003 | 0.714 | 0.512 | 0.593 | |
n=103. GOLD: Global Initiative for Chronic Obstructive Lung Disease; CAT: COPD assessment test; FEV1: forced expiratory volume in 1 s; #: Mann–Whitney U-test; ¶: Kruskal–Wallis test.